Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 9/20 | 1.00 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.73 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALPG | P10696 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.49 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.49 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149232 | 0.87 | PDE7A (0.78) | PDE7APDE7BPDE4BPDE4DLMNA | |
| SCHEMBL10924255 | 0.86 | PDE7A (0.76) | PDE7APDE7BPDE4BPDE4DLMNA | |
| SCHEMBL27581742 | 0.86 | PDE7A (0.75) | PDE7APDE7BPDE4BPDE4DLMNA | |
| SCHEMBL7607910 | 0.85 | PDE7A (0.78) | PDE7APDE7BPDE4BPDE4DLMNA | |
| SCHEMBL2030452 | 0.85 | PDE7A (0.74) | PDE7APDE7BPDE4BPDE4DLMNA | |
| SCHEMBL715750 | 0.84 | PDE7A (1.00) | PDE7APDE7BPDE4BPDE4DLMNA | |
| SCHEMBL7608814 | 0.83 | PDE7A (0.71) | PDE7APDE7BPDE4BPDE4DLMNA | |
| SCHEMBL6039967 | 0.82 | TXNRD1 (0.74) | PDE7APDE7BLMNAALDH1A1MAPT | |
| SCHEMBL8865858 | 0.82 | PDE7A (0.69) | PDE7APDE7BPDE4BPDE4DALDH1A1 | |
| SCHEMBL3029788 | 0.81 | PDE7A (0.68) | PDE7APDE7BPDE4BPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948440-B1 | ANTIVIRAL TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| EP-2948440-B1 | ANTIVIRAL TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9511059-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511059-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150353511-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150353511-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-10 | — | — | US | disclosed |
| EP-2948440-A1 | ANTIVIRAL TRIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-20140242028-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242028-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014114573-A1 | ANTIVIRAL TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114573-A1 | ANTIVIRAL TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140242028-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | PDE7A 3489/4885PDE7B 1110/4885PDE4B 947/4885 |
| US-20150353511-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | PDE7A 3489/4885PDE7B 1110/4885PDE4B 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.